National Cancer Institute, Research Contracts Branch, PSAS, 6120 Executive Blvd, EPS/Room 638, Bethesda, MD 20892-7227

B -- ORGANOCHLORINE COMPOUNDS, CYTOCHROME P4501A POLYMORPHISMS, AND BREAST CANCER RISK IN SHANGHAI CHINA SOL NCI-RFQ-90145-NV DUE 081199 POC Debbie Moore, Purchasing Agent (301) 402-4509, Todd Cole, Contracting Officer (301) 402-4509 The National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics plans to procure the analysis/serum assays of 500 blood samples of women between the ages of 25-64 who were newly diagnosed with breast cancer in Shanghai, China. The NCI plans to procure these services from Colorado State University, Department of Environmental Health, Ft. Collins, CO, 80523. This project was started as a collaborative study between the University of South Carolina and Colorado State University. The project is a case control study and it involves establishing the association between serum organchlorine compounds, P4501A1 polymorphisms, and breast cancer risk. At the current time the project is not being continued by the two universities. However, the NCI investigator, after learning about the available blood samples, is interested in this study and the data results due to the high incidence of breast cancer in Shanghai China, compared to other areas, as well as the high levels of DDE (5- to 8- fold higherthan in US population) and B-HCH (17-fold higher than in the US population). The continuation of this study will be of great value to the NCI. The University of Colorado has already analyzed 66 of the 500 blood samples for serum assays of organochlorine compounds under the collaboration agreement with South Carolina. The organochlorine compounds to be analyzed include pestisides: a-BHC, hexachlorobenzene, B-BHC, lindance, oxychordane, t-nonachlor, p, p-DDE, and p, p-DDT as well as the following PBCs: BZ#74, BZ#118, BZ#138, BZ#153, BZ#180, BZ183, and BZ#187. There is no blood remaining from the 66 samples that have already been analyzed. The continued analysis of the blood from The Analytical Laboratory at the Colorado State University is needed to insure that there is no compromise in the results of this study. Colorado State University is the only organization known to the NCI researcher that has such a supply of blood from the Shanghai region, an established case control study design with data on demographic and confounding factors for adjustment in data analysis, and established methods of analyzing serum samples for the noted compounds. This notice of intent is not a request for competitive proposals. However, if any interested party believes it can meet the above requirement, they may submit a statement of capabilities. Information furnished must be in writing and must contain sufficient detail, to allow NCI to determine if the party can meet the requirement. Capability statements must be received in the Contracting Office by 2:00 PM EST on August 11, 1999. If you have any questions, please contact Debbie Moore, Purchasing Agent on (301) 402-4509. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose determining whether to contact a competitive procurement. Posted 07/22/99 (W-SN357520). (0203)

Loren Data Corp. http://www.ld.com (SYN# 0016 19990726\B-0003.SOL)